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We have measured the activation of the small GTPase
Ral in human neutrophils after stimulation with fMet-
Leu-Phe (fMLP), platelet activating factor (PAF), and
granulocyte macrophage-colony stimulating factor and
compared it with the activation of two other small
GTPases, Ras and Rap1. We found that fMLP and PAF,
but not granulocyte macrophage-colony stimulating fac-
tor, induce Ral activation. All three stimuli induce the
activation of both Ras and Rap1. Utilizing specific inhib-
itors we demonstrate that fMLP-induced Ral activation
is mediated by pertussis toxin-sensitive G-proteins and
partially by Src-like kinases, whereas fMLP-induced
Ras activation is independent of Src-like kinases. PAF-
induced Ral activation is mediated by pertussis toxin-
insensitive proteins, Src-like kinases and phosphatidyl-
inositol 3-kinase. Phosphatidylinositol 3-kinase is not
involved in PAF-induced Ras activation. The calcium
ionophore ionomycin activates Ral, but calcium deple-
tion partially inhibits fMLP- and PAF-induced Ral acti-
vation, whereas Ras activation was not affected. In ad-
dition, 12-O-tetradecanoylphorbol-13-acetate-induced
activation of Ral is completely abolished by inhibitors of
protein kinase C, whereas 12-O-tetradecanoylphorbol-
13-acetate-induced Ras activation is largely insensitive.
We conclude that in neutrophils Ral activation is medi-
ated by multiple pathways, and that fMLP and PAF in-
duce Ral activation differently.
Neutrophils play an important role in the host defense to
invading microbial pathogens. Upon infection neutrophils be-
come activated through interaction with chemoattractants and
cytokines. These ligands bind to a variety of cell surface recep-
tors, including heterotrimeric G-protein-coupled receptors for
fMet-Leu-Phe (fMLP)1 and platelet activating factor (PAF),
and tyrosine kinase-associated receptors for granulocyte-mac-
rophage colony stimulating factor (GM-CSF). Receptor activa-
tion triggers intracellular signal transduction pathways, re-
sulting in the correct biological response, for instance,
migration, phagocytosis, antibody-dependent cell-mediated cy-
totoxicity, degranulation, and superoxide production. Improper
functioning of neutrophils is implicated in the pathogenesis of
a variety of inflammatory diseases resulting in tissue damage
(1–5).
Activation of small GTPases of the Ras superfamily is
thought to play a critical role in the regulation of neutrophil
function (6). For instance, Rac1 is implicated in the assembly of
the NADPH oxidase complex which generates the respiratory
burst and has been demonstrated to be activated (7). Also Ras
and its close relative Rap1 are rapidly activated after stimula-
tion of primary human neutrophils with fMLP, PAF, and GM-
CSF (8, 9), suggesting a role in initial events of neutrophil
activation. Ras controls the Raf-MEK-ERK kinase cascade and,
in addition, the regulation of the actin cytoskeleton (10, 11).
The function of Rap1 is still largely unclear, although for neu-
trophils it has been suggested that Rap1 plays a role in the
regulation of the respiratory burst (12, 13).
Recent attention has focused on the small GTPase Ral. Ral
comprises of two very closely related proteins RalA and RalB
and is abundantly expressed in human neutrophils. By yeast
two-hybrid analysis several Ral-specific guanine nucleotide ex-
change factors (Ral-GEFs) were found to bind directly to the
active, GTP-bound form of the small GTPases Ras, Rap1, and
two other close relatives, R-Ras and TC21 (14–18). This sug-
gested that Ral may be a downstream target for these Ras-like
GTPases. Indeed, in NIH3T3-A14 fibroblasts it was shown that
Ras mediates insulin and epidermal growth factor-induced ac-
tivation of Ral (19–22). In platelets, where Ral is also abun-
dantly expressed, Ral activation is mediated by calcium and
correlated with the activation of Rap1 rather than Ras (23).
Also in Rat2 fibroblasts Ral activation induced by epidermal
growth factor and endothelin is mediated by intracellular cal-
cium levels ([Ca21]i) independently of Ras (24, 25).
We have investigated fMLP- and PAF-induced Ral activation
in in human neutrophils and the possible involvement of Ras
and Rap1. In addition, utilizing specific inhibitors and [Ca21]i
depletion we analyzed the mechanism of Ral activation. From
the results obtained we conclude that in human neutrophils
Ral is a downstream target of both fMLP and PAF, each with
different signaling pathways toward Ral. Furthermore, we con-
clude that besides Ras and/or Rap1, [Ca21]i elevation, diacyl-
glycerol/PKC, Src-like kinases, and PI 3-kinase are involved in
the regulation of Ral activation.
EXPERIMENTAL PROCEDURES
Isolation of Human Neutrophils—Blood was obtained from healthy
volunteers from the Red Cross Blood Bank, Utrecht, The Netherlands.
Mixed granulocytes were isolated from the buffy-coat of 500 ml of 0.4%
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(w/v) trisodium citrate (pH 7.4)-treated blood as described previously
(26). Mononuclear cells were removed by centrifugation over isotonic
Percoll (1.078 g/ml) (Amersham Pharmacia Biotech). After lysis of the
erythrocytes in isotonic NH4Cl solution, neutrophils were washed and
resuspended in incubation buffer (20 mM HEPES, 132 mM NaCl, 6 mM
KCl, 1 mM MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 1 mM CaCl2) con-
taining 0.5% human serum albumin (Central Laboratory of The Neth-
erlands Red Cross Blood Transfusion Service, Amsterdam, The Neth-
erlands). Neutrophils were incubated for 30 min at 37 °C before
stimulation. Neutrophils isolated in this manner were unprimed. In all
experiments a concentration of 107 cells/ml was used for stimulation.
Neutrophil Stimulation—1 ml of neutrophil suspension was stimu-
lated with one of the following stimuli: fMLP (1 mM), PAF (1 mM), TPA
(100 ng/ml), thapsigargin (100 nM) (all from Sigma), GM-CSF (0.1 nM)
(Genzyme), and ionomycin (100 nM) (Calbiochem). In some experiments
cells were preincubated with GF109203X (5 mM), Ly294002 (10 mM),
PP1 (50 mM) (Biomol), Ro 31-8220 (5 mM) (Calbiochem), and PD98059
(10 mM) (Sigma). After stimulation 0.5 ml 3 3 Lysis buffer (1 3 Lysis
buffer: NaCl (100 mM), Tris-HCl (10 mM), pH 7.4, 1% Nonidet P-40, 10%
glycerol, MgCl2 (2 mM), phenylmethylsulfonyl fluoride (2 mM), benza-
midine (2 mM), aprotinin (2 mM), leupeptin (2 mM), trypsin inhibitor (2
mg/ml)) was added to lyse the cells.
Ral, Ras, and Rap1 Activation Assay—After stimulation and lysis,
samples were put on ice for 5 min and clarified by centrifugation at
14,000 rpm in an Eppendorf centrifuge for 8 min at 4 °C. Per cell lysate
100 ml of bacterial lysate containing GST-Ral-binding domain of
RLIP76 (GST-RLIP-RBD) and 100 ml of bacterial lysate containing
GST-Rap-binding domain of Ral GDS (GST-RalGDS-RBD) or 100 ml of
bacterial lysate containing GST-Ras-binding domain of Raf (GST-Raf-
RBD) isolated as described in Refs. 23, 27, and 28, was precoupled for
1 h to 50 ml of 10% glutathione beads. After coupling, beads were
washed 4 times with Lysis buffer, added to the cell lysate and incubated
for 30 min at 4 °C. Samples were washed 3 times in Lysis buffer and
bound proteins were eluted in 15 ml of Laemmli sample buffer. The
samples were separated by SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membranes (Immobilon-P, Mil-
lipore). RalA and Rap1 were detected with monoclonal antibodies
(Transduction Laboratories) and horseradish peroxidase-coupled goat
anti-mouse (Bio-Rad) using enhanced chemiluminescence (NEN Life
Science Products Inc.). To detect Ras Y13–259 and horseradish perox-
idase-coupled rabbit anti-rat (Santa Cruz) were used. RalB was de-
tected with a goat polyclonal (Santa Cruz) and horseradish peroxidase-
coupled donkey anti-goat (Santa Cruz). Band intensities were
measured after scanning the blots with the use of NIH image 1.62
(Macintosh). All experiments were done at least three times and rep-
resentative experiments are shown.
ERK2 Phosphorylation—106 Neutrophils were stimulated and lysed
in 1% Triton, 150 mM NaCl, 50 mM Tris-NaCl (pH 8.0), 400 mM NaVO4,
benzamidine (2 mM), aprotinin (2 mM), and leupeptin (2 mM). 5 3 Lae-
mmli sample buffer was added and samples were boiled for 5 min at
95 °C. Phosphorylated ERK was detected as described previously (29).
Samples were put on 10% SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride. ERK2 was detected with poly-
clonal antibodies and horseradish peroxidase-coupled goat anti-rabbit
using enhanced chemiluminescence.
Depletion of Intracellular Free Ca21—Neutrophils were Ca21 de-
pleted as described before (30). Neutrophils were suspended in Ca21-
free incubation buffer supplemented with 1 mM EGTA. Indo-1/AM
(Molecular Probes) was added to 1-ml aliquots of suspended cells (107
cells/ml) at a final concentration of 1.5 mM and incubated for 40 min at
37 °C. To deplete the internal Ca21 stores, 100 nM thapsigargin was
added 10 min prior to washing. Cells were washed once with Ca21-free
incubation buffer containing 1 mM EGTA. Under these conditions we
did not observe any increase in intracellular calcium when the cells
were treated with fMLP (not shown, but see Ref. 9).
RESULTS
fMLP and PAF Induce Ral Activation—Utilizing activation-
specific probes which recognize the active GTP-bound form, but
not the inactive GDP-bound form of small GTPases (23, 27, 28),
we have analyzed activation of Ral, Ras, and Rap1 after stim-
ulation with fMLP. As shown in Fig. 1A treatment of resting
primary human neutrophils with fMLP (1 mM) resulted in a
very rapid but transient activation of Ral. Activation was max-
imal after 30 s and returned to basal levels after 10 min. The
pattern of activation was the same in every experiment but the
maximal fold activation was donor-specific and varied between
5- and 25-fold.
A similar activation profile was observed for Ras, whereas
Rap1 showed the biphasic activation with a major peak at 30 s
and a minor peak at 5 min as reported previously (9). Activa-
tion of Ral was already observed with fMLP at 1 nM and
maximal at 10 nM. Ras activation showed a similar sensitivity
for fMLP (Fig. 1B). Maximal Rap1 activation was already de-
tected after 1 nM fMLP stimulation. This demonstrated that,
similar to Ras and Rap1, Ral is very rapidly activated by fMLP
at a concentration known to induce neutrophil effector func-
tions (8, 31, 32).
Ral activation was also observed after stimulation of neutro-
phils with PAF (Fig. 1C). Activation peaked between 30–60 s
and decreased afterward. After 10 min PAF stimulation, no
significant Ral activation was detected. Ras followed similar
kinetics as Ral, whereas Rap1 activation was still detected
after 10 min.
FIG. 1. fMLP- and PAF-induced activation of the small
GTPases Ral, Rap1, and Ras. A, neutrophils were stimulated with 1
mM fMLP for the time indicated. Ral and Rap1 or Ras activity were
determined in the same cell lysate by precipitating the GTP-bound
GTPases with activation specific probes: for Rap1 (RalGDS-RBD), Ras
(Raf-RBD), and Ral (RLIP76-RBD). After gel electrophoresis and West-
ern blotting, Ral, Ras, and Rap1 were detected with mouse monoclonals
against Rap1, Ras, and Ral. B, neutrophils were stimulated with vari-
ous concentrations of fMLP for 10 s or 1 min for Ral and Rap1 activity,
or Ras and Ral activity were determined as described in A. C, PAF-
induced activation of the small GTPases Ral, Rap1, and Ras. Neutro-
phils were stimulated with 1 mM PAF. Stimulations and activation
assays were done as described in A. Elevated levels of Ral and Ras GTP
in the lower panel at 10 min was observed in two out of nine experi-
ments and is a clear example of donor variation. The top panel is from
a different donor and Ral-GTP is low. D, neutrophils were stimulated
and lysed as described in A. Next to the pull downs, 1 and 3% of the
original amount of neutrophil lysates were put on gel. Quantification of
the amount of Ral-GTP detected after fMLP and PAF stimulation
indicates that about 5% of Ral is recovered with the use of RLIP76-RBD.
E, neutrophils were stimulated and lysed as described in A. RalB was
detected with a aRalB.
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With the use of RLIP76-RBD, 5–10% of Ral-GTP is recovered
(23). Because approximately 4–5% of the total amount of Ral
present in neutrophils is recovered by RLIP76-RBD (Fig. 1D)
after fMLP stimulation, this implied that a significant amount
of Ral is in the GTP bound state.
With the use of a RalB specific antibody we could also detect
RalB activation after 1 min fMLP and PAF stimulation. Ap-
parently both RalA and RalB are activated in neutrophils.
Because the RalA antibody is more sensitive than the RalB
antibody we focussed on the activation mechanism of Ral de-
tected with the RalA antibody.
GM-CSF Activates Ras and Rap1, but Not Ral—We have
measured Ral activation after GM-CSF stimulation and as
shown in Fig. 2A, Ral was not significantly activated in the first
20 min after stimulation. Interestingly GM-CSF did induce
both Ras and Rap1 activation (Fig. 2A). Furthermore, GM-CSF
induced Ras activation was comparable to fMLP and PAF in-
duced Ras activation (Fig. 2, B and C), suggesting that the level
of Ras activation is not the limiting factor for Ral activation. A
downstream target of Ras, ERK was activated after GM-CSF
stimulation (Fig. 2D), indicating that the GM-CSF induced Ras
activation is functional toward downstream targets. This im-
plies that GM-CSF either induces an inhibitory signal which
prevents Ras (and/or Rap1) mediated activation of Ral, or that
Ras (and/or Rap1) activation is not sufficient for Ral activation.
To discriminate between these two possibilities, we treated
neutrophils for 10 min with GM-CSF and subsequently with
fMLP. We did not observe any inhibitory effect of GM-CSF on
fMLP-induced Ral activation (Fig. 2E). This implies that GM-
CSF-induced Ras (and/or Rap1) is not sufficient for Ral
activation.
Calcium and Diacylglycerol Signaling Activate Ral—If in-
deed Ras (and/or Rap1) activation is not sufficient for Ral
activation, it may be that fMLP- and PAF-induced Ral activa-
tion is not mediated by Ras (and/or Rap1) but via different
signaling pathways not induced by GM-CSF.
After stimulation with fMLP or PAF, phospholipase b is
activated resulting in diacylglycerol-mediated activation of pro-
tein kinase C (PKC) and inositol 1,4,5-triphosphate-mediated
Ca21 mobilization (6, 33). Since an increase in [Ca21]i has been
implicated in the activation of Ral (23, 24) and GM-CSF does
not give rise to [Ca21]i (30) in neutrophils, we have investigated
whether calcium is involved in Ral activation in neutrophils.
Indeed, the calcium ionophore ionomycin did induce the acti-
vation of Ral, showing that changes in [Ca21]i are sufficient to
induce Ral activation (Fig. 3A). However, only an inhibition of
the early fMLP-induced Ral activation, at 10 s, was observed in
calcium-depleted neutrophils, indicating that a change in
[Ca21]i is not the sole mechanism by which fMLP can activate
Ral. Compared with the fMLP-induced Ral activation, PAF-
induced Ral activation is more sensitive to calcium depletion.
Not only the 10-s induced Ral activation is blocked, but also the
1-min Ral activation is inhibited by more than 50% (Fig. 3, B
and C). Calcium depletion did not affect the 10-s fMLP- and
PAF-induced Ras activation (Fig. 3, B and C), indicating that
the calcium-dependent Ral activation is unlikely to be medi-
ated via Ras.
Although GM-CSF induces diacylglycerol formation, there is
no evidence that classical PKCs are activated (34, 35). There-
fore we also investigated the involvement of PKC in Ral acti-
vation. As shown in Fig. 4 TPA is a strong activator of both Ral
and Ras (Fig. 4) and Rap1 (9). To investigate whether TPA-
induced Ral activation is mediated via PKC we used the protein
kinase C inhibitors bisindolylmaleimide (GF109203X) and Ro
31-8220. Interestingly, these inhibitors did not or only partially
inhibited TPA-induced activation of Ras, whereas TPA-induced
Ral activation was completely inhibited. These results indi-
cated that TPA-induced Ral activation is mediated via PKC
and not via Ras.
We next investigated whether PKC is an essential compo-
FIG. 2. Ral activation after GM-CSF stimulation. A, neutrophils
were stimulated with 0.1 nM GM-CSF as described in the legend to Fig.
1A. B, levels of Ras activation after 1 min fMLP (1 mM), 1 min PAF (1
mM), and 10 min GM-CSF (0.1 nM) stimulation were compared. Activa-
tion was determined as described in the legend to Fig. 1A. C, the
amount of Ral- and Ras-GTP of Fig. 3B was quantified and depicted as
fold induction compared with the amount of Ral- and Ras-GTP detected
in non-stimulated neutrophils. D, activation of ERK after stimulation
with 1 min fMLP (1 mM) or 10 min GM-CSF (0.1 nM) was determined by
mobility shifts. ERK-P is the active form. E, GM-CSF has no inhibitory
effect on fMLP-induced Ral activation. Neutrophils were treated for 20
min with 0.1 nM GM-CSF. Afterward neutrophils were stimulated with
1 mM fMLP for the indicated time points. Ral and Ras activation was
determined as described.
FIG. 3. Calcium dependence of Ral activation. A, Ral and Ras
activation after stimulation with 100 nM ionomycin for the indicated
time points. B, neutrophils were depleted of intracellular Ca21. After-
ward neutrophils were stimulated with 1 mM fMLP or 1 mM PAF. C, the
amount of Ral-GTP detected in calium-depleted neutrophils was quan-
tified and depicted as % activation. 100% is the induction of Ral-GTP
detected after fMLP or PAF stimulation for the indicated time in control
neutrophils.
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nent in fMLP- and PAF-induced activation of Ral. However, the
fMLP-induced activation of both Ral and Ras was not affected
by both inhibitors (Fig. 4). Also PAF-induced Ral and Ras
activation is not affected by Ro 31-8220 (Fig. 4). These results
show that fMLP- and PAF-mediated Ral activation can be
independent of PKCs. Double inhibition of fMLP stimulation by
calcium depletion and GF109203X only partially inhibited, but
did not block fMLP-induced Ral activation (Fig. 5), again indi-
cating that fMLP-induced Ral activation can be independent of
changes in [Ca21]i and PKCs.
PI 3-Kinase and Src-like Kinases Partially Mediate Ral Ac-
tivation—In search for an additional pathway toward Ral ac-
tivation we tested whether PI 3-kinase is involved in fMLP-
and PAF-induced Ral activation, since PI 3-kinase is impli-
cated in fMLP- and PAF-induced signaling (8, 36). Ly294002, a
PI 3-kinase inhibitor did not inhibit the fMLP-induced Ral
activation, whereas the PAF-induced Ral activation was par-
tially inhibited (Fig. 6A). Neither fMLP- nor PAF-induced Ras
activation are inhibited by LY294002 (Fig. 6B). These results
indicated that besides calcium and PKC, PI 3-kinase can me-
diate PAF-induced Ral activation.
In addition, we tested whether fMLP- and PAF-induced Ral
activation is mediated by Src-like kinases, which are known to
be phosphorylated after fMLP and PAF stimulation (6, 33).
After inhibition of Src-like kinases with PP1 (37), both the
fMLP- and PAF-induced Ral activation were partially inhib-
ited, under conditions that fMLP-induced respiratory burst
was completely blocked (data not shown). The PP1 inhibition
on PAF-induced Ral activation is more severe (Fig. 6A). fMLP-
induced Ras activation is also, but mildly, affected by inhibition
with PP1, whereas the PAF induced Ras activation is inhibited
by approximately 75% (Fig. 6B). These results indicate that
Src-like kinases partially mediate fMLP- and, more clearly,
PAF-induced Ral and Ras activation. PD98059, a MEK inhib-
itor did not inhibit fMLP- and PAF-induced Ral and Ras acti-
vation, indicating that fMLP- and PAF-induced Ral and Ras
activation are independent of MEK (Fig. 6).
Difference in Signal Transduction Toward Ral between fMLP
and PAF—Our results suggested that fMLP-induced Ral acti-
vation is regulated differently than PAF-induced Ral activa-
tion. It is known that PAF and fMLP mediate signaling via
different G-proteins. For instance, PAF-induced Ca21 mobili-
zation is not inhibited by pertussis toxin, whereas the fMLP-
induced Ca21 mobilization is (38, 39). Therefore we tested
whether fMLP- and PAF-induced Ral activation could be
blocked by preincubation with pertussis toxin. Indeed fMLP-
induced Ral activation is inhibited by approximately 80%, but
PAF-induced Ral activation is only inhibited by 20% (Fig. 7).
From these results we concluded that the fMLP-induced Ral
activation is mostly regulated by pertussis toxin-sensitive G-
proteins, whereas the PAF-induced Ral activation is mostly
regulated by pertussis toxin-insensitive G-proteins.
DISCUSSION
In this study we show that the small GTPase Ral is rapidly
activated after stimulation of primary human neutrophils with
fMLP and PAF with similar kinetics as observed for the acti-
vation of Ras and Rap1. This correlation in activation between
Ras and Ral is compatible with the finding that Ral activation
is mediated by direct binding of Ras to exchange factors for Ral
(RalGEFs) (19–22). Also Rap1 may mediate the activation of
Ral, since Rap1 binds to Ral-GEFs in vitro (14, 15, 18) and in
co-transfection studies in COS7 cells, active Rap1 induces Ral
activation (25). Surprisingly, although GM-CSF did induce the
activation of both Ras and Rap1, it fails to induce Ral activa-
tion. This implies that in neutrophils Ras and Rap1 activation
does not necessarily lead to Ral activation.
It is unlikely that an inhibitory signal by GM-CSF results in
the failure of Ras and/or Rap1 to activate Ral, since GM-CSF
did not inhibit fMLP-induced Ral activation. More plausible
explanations would be either that: (i) GM-CSF fails to provide
FIG. 5. Inhibition of both calcium and PKC signaling only par-
tially inhibits fMLP-induced Ral activation. Neutrophils were cal-
cium depleted and pretreated with 3 mM GF109203X or solvent for 10
min. Afterward neutrophils were stimulated with 1 mM fMLP for the
indicated time points. Ral activation was determined as described in
the legend Fig. 1A. 100% is the induction of Ral-GTP detected after
fMLP or PAF stimulation for the indicated time in control neutrophils.
FIG. 4. PKC is not involved in fMLP- and PAF-induced Ral and Ras activation, whereas TPA-induced Ral activation is inhibited
by PKC inhibitors. A, neutrophils were pretreated with 3 mM GF109203X, 5 mM Ro 31–8220, or solvent for 10 min. Afterward neutrophils were
stimulated with 1 mM fMLP for 1 min or 100 ng/ml TPA for 5 min. Neutrophils were only pretreated with 5 mM Ro 31–8220 in the case of 1 mM PAF
stimulation. Ras and Ral activations were determined as described in legend to Fig. 1A. B, detected Ral- and Ras-GTP were quantified and depicted
as described in the legend to Fig. 3C. 100% is the induction of Ral-GTP detected from stimulated neutrophils treated with solvent. C, neutrophils
were pretreated with 5 mM Ro 31–8220 or solvent for 10 min. Afterward neutrophils were stimulated with 1 mM PAF for 1 min. Ras and Ral
activation were determined as described in legend to Fig. 1A. 100% is the induction of Ral-GTP detected from stimulated neutrophils treated with
solvent.
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an essential auxiliary signal, (ii) GM-CSF activates a pool of
Ras and Rap1 which is spatially separated from Ral-GEF and
Ral, or (iii) Ral activation is independent of Ras and Rap1.
An alternative signaling pathway implicated in Ral activa-
tion is a change in [Ca21]i (23–25). Thus, if Ras and/or Rap1 are
indeed unable to activate Ral, calcium may be responsible for
fMLP- and PAF-induced Ral activation. This would be compat-
ible with the notion that GM-CSF does not induce an increase
in [Ca21]i (30, 40). Indeed, in neutrophils the calcium ionophore
ionomycin induces Ral activation, showing that a rise in [Ca21]i
is sufficient to activate Ral. However, both calcium-dependent
and -independent pathways are used by fMLP and PAF to
activate Ral. Because calcium depletion only partially affected
Ral activation and did not affect the fMLP-induced Ras and
Rap1 activation (9), this again indicated that Ras and Rap1
activation are not sufficient for Ral activation.
After stimulation of neutrophils with the phorbol ester TPA
we observed activation of Ral, as well as Ras and Rap1 (9).
Since TPA-induced Ral activation is sensitive to PKC inhibi-
tors, this Ral activation is likely to be mediated by PKC. In
contrast, Ras and Rap1 activation by TPA are largely inde-
pendent of PKC (9 and Fig. 4). Most likely TPA-induced Ras
and Rap1 activation is mediated by specific GEFs with diacyl-
glycerol-binding domains (41–43). It should be noted that both
in platelets and Rat1 NIH3T3-A14 fibroblasts, TPA fails to
activate Ral, showing the cell type specificity of the regulation
of Ral activation (25, 44).
fMLP-induced Ral activation was insensitive to PKC inhib-
itors and, in addition, inhibition by both calcium depletion and
GF109203X only partially inhibited fMLP-induced Ral activa-
tion. This implies that besides diacylglycerol to activate PKC
and calcium, other mediators of Ral activation may exist. Also
PAF-induced Ral activation is insensitive to PKC inhibition,
indicating that PAF may activate Ral by mediators other than
calcium and PKC as well. To obtain further insight into a
calcium and PKC independent pathway, we investigated
fMLP- and PAF-induced Ral activation after pretreatment with
various pharmacological inhibitors.
fMLP-induced Ral activation is insensitive to PI 3-kinase
inhibition, whereas PAF-induced Ral activation is partially
inhibited by PI 3-kinase inhibition. This implies that PI 3-ki-
nase may, in part, be involved in PAF-induced Ral activation.
In accordance with previous reports in which tyrosine ki-
nase-independent fMLP-induced Ras activation was found (48,
49), fMLP-induced Ras activation is independent of Src-like
kinases. In contrast fMLP-induced Ral activation can be par-
tially mediated by Src-like kinases. After PAF stimulation not
only Ral but also Ras activation is mediated by Src-like ki-
nases, suggesting that PAF and fMLP activate Ras and Ral by
a different mechanism.
In addition, calcium depletion inhibited PAF-induced Ral
activation more strongly than fMLP-induced Ral activation.
Pertussis toxin inhibited fMLP-induced Ral activation,
whereas PAF-induced Ral activation was largely insensitive to
the same treatment, indicating that fMLP-induced signaling is
mediated by pertussis toxin-sensitive Ga-proteins, as Gi2 (50,
51), whereas PAF-induced signaling is mediated by pertussis
toxin-insensitive G-proteins, as Gi3, Gas, or Gaq (52). This is in
agreement with previous reports, where pertussis toxin inhib-
ited fMLP-induced elevation of [Ca21]i, but not PAF induced
elevation of [Ca21]i (38, 39).
The biological function for Ral in neutrophils is still unclear.
Since Ral is activated only after fMLP and PAF stimulation,
FIG. 6. PAF-induced Ral activation is partially mediated by PI
3-kinase, whereas the fMLP-induced Ral activation is PI 3-ki-
nase independent. Neutrophils were pretreated with 10 mM PD98059,
10 mM LY294002, 50 mM PP1, or solvent for 10 min. Afterward neutro-
phils were stimulated with 1 mM fMLP or 1 mM PAF for 1 min. A, Ral
activation was determined and quantified as described in legends to
Figs. 1A and 3C. 100% is the induction of Ral-GTP detected from
stimulated neutrophils treated with solvent. B, Ras activation deter-
mined and quantified as described in legends to Figs. 1A and 3C. 100%
is the induction of Ral-GTP detected from stimulated neutrophils
treated with solvent.
FIG. 7. Pertussis toxin inhibits fMLP-induced Ral activation but not PAF-induced Ral activation. Neutrophils were pretreated with
300 ng/ml pertussis toxin or solvent for 1 h. Afterward neutrophils were stimulated with 1 or 0.1 mM fMLP or 1 or 0.1 mM PAF for 1 min. Ral
activation was determined and quantified as described in the legends to Figs. 1A and 3C. 100% is the induction of Ral-GTP detected from
stimulated neutrophils treated with solvent.
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but not after GM-CSF stimulation, Ral may be involved in a
cellular response specific for fMLP and PAF, such as chemo-
taxis (directional cell movement), endo-/phagocytosis, degran-
ulation, and respiratory burst. In the active GTP-bound form,
Ral associates with RLIP76 (53, 54). This protein is a GTPase-
activating protein for the small GTPase Cdc42, a GTPase in-
volved in the control of filopodia formation in fibroblasts (55)
and chemotaxis in macrophages (56). Recently it was reported
that Ral in the GTP bound form also binds to ABP280/filamin
1, a protein involved in cross-linking of actin filaments. This
complex may mediate Cdc42-induced filopodia formation (57).
Furthermore, it has been suggested that RLIP76 may have a
function in endocytosis via recently discovered Reps1 and
POB1 (58, 59). Finally, Ral was reported to associate with the
small GTPase Arf and phospholipase D1 in a nucleotide inde-
pendent manner (60–63). Both phospholipase D1 and Arf are
implicated in neutrophil vesicle transport and degranulation
(64). Although the physiological relevance of these interactions
remains to be established, they may indicate that Ral plays a
role in the control of the actin cytoskeleton and processes
related to this, such as establishing cell polarity, migration,
and vesicular transport (55, 64).
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